{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:06:51Z","timestamp":1792667211016,"version":"4.5.0"},"reference-count":34,"publisher":"National Academy of Sciences","issue":"38","content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2014,9,23]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>Microtubules are dynamic protein filaments assembled from tubulin subunits, which play a key role for cell division. Ligands that target microtubules and affect their dynamics belong to the most successful classes of chemotherapeutic drugs against cancer by inhibiting cell proliferation. Here we have analyzed three structurally unrelated drugs that destabilize microtubules, using X-ray crystallography. The data reveal a new tubulin-binding site for these drugs, which renders their mechanism of action distinct from that of other types of microtubule assembly inhibitors. Similar key interactions with tubulin are observed for all three ligands, thus defining a common pharmacophore. Our results offer an opportunity for the rational design of potent tubulin modulators for the development of more efficient cancer therapies.<\/jats:p>","DOI":"10.1073\/pnas.1408124111","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T02:59:19Z","timestamp":1407812359000},"page":"13817-13821","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":281,"title":["A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs"],"prefix":"10.1073","volume":"111","author":[{"given":"Andrea E.","family":"Prota","sequence":"first","affiliation":[{"name":"Department of Biology and Chemistry, Laboratory of Biomolecular Research, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Bargsten","sequence":"additional","affiliation":[{"name":"Department of Biology and Chemistry, Laboratory of Biomolecular Research, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Fernando","family":"Diaz","sequence":"additional","affiliation":[{"name":"Chemical and Physical Biology, Centro de Investigaciones Biol\u00f3gicas, Consejo Superior de Investigaciones Cient\u00edficas CIB-CSIC, 28040 Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Marsh","sequence":"additional","affiliation":[{"name":"Swiss Light Source, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cuevas","sequence":"additional","affiliation":[{"name":"PharmaMar S.A., 28770 Madrid, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Liniger","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Z\u00fcrich, 8093 Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Neuhaus","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Z\u00fcrich, 8093 Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Andreu","sequence":"additional","affiliation":[{"name":"Chemical and Physical Biology, Centro de Investigaciones Biol\u00f3gicas, Consejo Superior de Investigaciones Cient\u00edficas CIB-CSIC, 28040 Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"Altmann","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Z\u00fcrich, 8093 Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel O.","family":"Steinmetz","sequence":"additional","affiliation":[{"name":"Department of Biology and Chemistry, Laboratory of Biomolecular Research, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2014,8,11]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: A dynamic field of cancer therapeutics","volume":"9","author":"Dumontet C","year":"2010","unstructured":"C Dumontet, MA Jordan, Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 9, 790\u2013803 (2010).","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan MA","year":"2004","unstructured":"MA Jordan, L Wilson, Microtubules as a target for anticancer drugs. Nat Rev Cancer 4, 253\u2013265 (2004).","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2174\/092986709787846488","article-title":"Tubulin: A target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system","volume":"16","author":"Canta A","year":"2009","unstructured":"A Canta, A Chiorazzi, G Cavaletti, Tubulin: A target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem 16, 1315\u20131324 (2009).","journal-title":"Curr Med Chem"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd3980","article-title":"Antibody-drug conjugates","volume":"12","author":"Zolot RS","year":"2013","unstructured":"RS Zolot, S Basu, RP Million, Antibody-drug conjugates. Nat Rev Drug Discov 12, 259\u2013260 (2013).","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1056\/NEJMe1211736","article-title":"The promise of antibody-drug conjugates","volume":"367","author":"Teicher BA","year":"2012","unstructured":"BA Teicher, JH Doroshow, The promise of antibody-drug conjugates. N Engl J Med 367, 1847\u20131848 (2012).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers EL","year":"2013","unstructured":"EL Sievers, PD Senter, Antibody-drug conjugates in cancer therapy. Annu Rev Med 64, 15\u201329 (2013).","journal-title":"Annu Rev Med"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/bjc.1996.68","article-title":"Phase II clinical trials with rhizoxin in breast cancer and melanoma","volume":"73","author":"Hanauske AR","year":"1996","unstructured":"AR Hanauske, et al., Phase II clinical trials with rhizoxin in breast cancer and melanoma. Br J Cancer; The EORTC Early Clinical Trials Group 73, 397\u2013399 (1996).","journal-title":"Br J Cancer"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.1016\/S0021-9258(17)44880-0","article-title":"Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites","volume":"265","author":"Bai RL","year":"1990","unstructured":"RL Bai, GR Pettit, E Hamel, Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265, 17141\u201317149 (1990).","journal-title":"J Biol Chem"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0304-4165(87)90206-6","article-title":"Rhizoxin binding to tubulin at the maytansine-binding site","volume":"926","author":"Takahashi M","year":"1987","unstructured":"M Takahashi, et al., Rhizoxin binding to tubulin at the maytansine-binding site. Biochim Biophys Acta 926, 215\u2013223 (1987).","journal-title":"Biochim Biophys Acta"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0163-7258(92)90028-X","article-title":"Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B","volume":"55","author":"Hamel E","year":"1992","unstructured":"E Hamel, Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55, 31\u201351 (1992).","journal-title":"Pharmacol Ther"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1021\/ja00759a054","article-title":"Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus","volume":"94","author":"Kupchan SM","year":"1972","unstructured":"SM Kupchan, et al., Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 94, 1354\u20131356 (1972).","journal-title":"J Am Chem Soc"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"S Verma, et al., Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med; EMILIA Study Group 367, 1783\u20131791 (2012).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"10164","DOI":"10.1021\/ja404578u","article-title":"Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds","volume":"135","author":"Mart\u00edn MJ","year":"2013","unstructured":"MJ Mart\u00edn, et al., Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds. J Am Chem Soc 135, 10164\u201310171 (2013).","journal-title":"J Am Chem Soc"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1021\/cb400461j","article-title":"New interfacial microtubule inhibitors of marine origin, PM050489\/PM060184, with potent antitumor activity and a distinct mechanism","volume":"8","author":"Pera B","year":"2013","unstructured":"B Pera, et al., New interfacial microtubule inhibitors of marine origin, PM050489\/PM060184, with potent antitumor activity and a distinct mechanism. ACS Chem Biol 8, 2084\u20132094 (2013).","journal-title":"ACS Chem Biol"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0006-291X(76)90958-X","article-title":"Binding of maytansine to rat brain tubulin","volume":"72","author":"Mandelbaum-Shavit F","year":"1976","unstructured":"F Mandelbaum-Shavit, MK Wolpert-DeFilippes, DG Johns, Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 72, 47\u201354 (1976).","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_4_16_2","first-page":"1889","article-title":"Derivatives of 5,6-diphenylpyridazin-3-one: Synthetic antimitotic agents which interact with plant and mammalian tubulin at a new drug-binding site","volume":"46","author":"Batra JK","year":"1986","unstructured":"JK Batra, LJ Powers, FD Hess, E Hamel, Derivatives of 5,6-diphenylpyridazin-3-one: Synthetic antimitotic agents which interact with plant and mammalian tubulin at a new drug-binding site. Cancer Res 46, 1889\u20131893 (1986).","journal-title":"Cancer Res"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1083\/jcb.201211017","article-title":"Structural basis of tubulin tyrosination by tubulin tyrosine ligase","volume":"200","author":"Prota AE","year":"2013","unstructured":"AE Prota, et al., Structural basis of tubulin tyrosination by tubulin tyrosine ligase. J Cell Biol 200, 259\u2013270 (2013).","journal-title":"J Cell Biol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1126\/science.1230582","article-title":"Molecular mechanism of action of microtubule-stabilizing anticancer agents","volume":"339","author":"Prota AE","year":"2013","unstructured":"AE Prota, et al., Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science 339, 587\u2013590 (2013).","journal-title":"Science"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1002\/anie.201300576","article-title":"Total synthesis of the tubulin inhibitor WF-1360F based on macrocycle formation through ring-closing alkyne metathesis","volume":"52","author":"Neuhaus CM","year":"2013","unstructured":"CM Neuhaus, M Liniger, M Stieger, KH Altmann, Total synthesis of the tubulin inhibitor WF-1360F based on macrocycle formation through ring-closing alkyne metathesis. Angew Chem Int Ed Engl 52, 5866\u20135870 (2013).","journal-title":"Angew Chem Int Ed Engl"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.7164\/antibiotics.39.762","article-title":"A new antitumor complex, WF-1360, WF-1360A, B, C, D, E and F","volume":"39","author":"Kiyoto S","year":"1986","unstructured":"S Kiyoto, et al., A new antitumor complex, WF-1360, WF-1360A, B, C, D, E and F. J Antibiot (Tokyo) 39, 762\u2013772 (1986).","journal-title":"J Antibiot (Tokyo)"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature03566","article-title":"Structural basis for the regulation of tubulin by vinblastine","volume":"435","author":"Gigant B","year":"2005","unstructured":"B Gigant, et al., Structural basis for the regulation of tubulin by vinblastine. Nature 435, 519\u2013522 (2005).","journal-title":"Nature"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/embor.2008.171","article-title":"Structural insight into the inhibition of tubulin by vinca domain peptide ligands","volume":"9","author":"Cormier A","year":"2008","unstructured":"A Cormier, M Marchand, RB Ravelli, M Knossow, B Gigant, Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep 9, 1101\u20131106 (2008).","journal-title":"EMBO Rep"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1107\/S0907444912017143","article-title":"Structural plasticity of tubulin assembly probed by vinca-domain ligands","volume":"68","author":"Ranaivoson FM","year":"2012","unstructured":"FM Ranaivoson, B Gigant, S Berritt, M Joulli\u00e9, M Knossow, Structural plasticity of tubulin assembly probed by vinca-domain ligands. Acta Crystallogr D Biol Crystallogr 68, 927\u2013934 (2012).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1006\/jmbi.2001.5077","article-title":"Refined structure of alpha beta-tubulin at 3.5 A resolution","volume":"313","author":"L\u00f6we J","year":"2001","unstructured":"J L\u00f6we, H Li, KH Downing, E Nogales, Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol 313, 1045\u20131057 (2001).","journal-title":"J Mol Biol"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00260855","article-title":"Rhizoxin resistant mutants with an altered beta-tubulin gene in Aspergillus nidulans","volume":"220","author":"Takahashi M","year":"1989","unstructured":"M Takahashi, H Kobayashi, S Iwasaki, Rhizoxin resistant mutants with an altered beta-tubulin gene in Aspergillus nidulans. Mol Gen Genet 220, 53\u201359 (1989).","journal-title":"Mol Gen Genet"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","article-title":"Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules","volume":"9","author":"Lopus M","year":"2010","unstructured":"M Lopus, et al., Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9, 2689\u20132699 (2010).","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"66","author":"Erickson HK","year":"2006","unstructured":"HK Erickson, et al., Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66, 4426\u20134433 (2006).","journal-title":"Cancer Res"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7164\/antibiotics.44.66","article-title":"Studies on macrocyclic lactone antibiotics. XIII. Anti-tubulin activity and cytotoxicity of rhizoxin derivatives: Synthesis of a photoaffinity derivative","volume":"44","author":"Kato Y","year":"1991","unstructured":"Y Kato, et al., Studies on macrocyclic lactone antibiotics. XIII. Anti-tubulin activity and cytotoxicity of rhizoxin derivatives: Synthesis of a photoaffinity derivative. J Antibiot (Tokyo) 44, 66\u201375 (1991).","journal-title":"J Antibiot (Tokyo)"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bcp.2014.01.026","article-title":"PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors","volume":"88","author":"Mart\u00ednez-D\u00edez M","year":"2014","unstructured":"M Mart\u00ednez-D\u00edez, et al., PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. Biochem Pharmacol 88, 291\u2013302 (2014).","journal-title":"Biochem Pharmacol"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain","volume":"428","author":"Ravelli RB","year":"2004","unstructured":"RB Ravelli, et al., Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428, 198\u2013202 (2004).","journal-title":"Nature"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0092-8674(00)80961-7","article-title":"High-resolution model of the microtubule","volume":"96","author":"Nogales E","year":"1999","unstructured":"E Nogales, M Whittaker, RA Milligan, KH Downing, High-resolution model of the microtubule. Cell 96, 79\u201388 (1999).","journal-title":"Cell"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1083\/jcb.201007081","article-title":"Template-free 13-protofilament microtubule-MAP assembly visualized at 8 A resolution","volume":"191","author":"Fourniol FJ","year":"2010","unstructured":"FJ Fourniol, et al., Template-free 13-protofilament microtubule-MAP assembly visualized at 8 A resolution. J Cell Biol 191, 463\u2013470 (2010).","journal-title":"J Cell Biol"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter PD","year":"2012","unstructured":"PD Senter, EL Sievers, The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30, 631\u2013637 (2012).","journal-title":"Nat Biotechnol"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-59745-442-1_2","article-title":"Large scale purification of brain tubulin with the modified Weisenberg procedure","volume":"137","author":"Andreu JM","year":"2007","unstructured":"JM Andreu, Large scale purification of brain tubulin with the modified Weisenberg procedure. Methods Mol Med 137, 17\u201328 (2007).","journal-title":"Methods Mol Med"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1408124111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T07:38:57Z","timestamp":1654587537000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1408124111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,11]]},"references-count":34,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2014,9,23]]}},"alternative-id":["10.1073\/pnas.1408124111"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1408124111","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,11]]},"assertion":[{"value":"2014-08-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}